 EMERYVILLE, Calif., Oct. 10, 2021 GLOBE NEWSWIRE -- 4D Molecular Therapeutics Nasdaq: FDMT, a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced interim safety and clinical activity data from the Phase 12 clinical trial of intravitreal 4D-125 in patients with advanced X-linked retinitis pigmentosa XLRP. The interim data were presented today in a late-breaking presentation at the American Society of Retina Specialists ASRS 39th Annual Meeting. 